Cardiovascular Research

Since 1915 the Henry Ford Health System and the Division of Cardiology have shared the common mission of improving human life through excellence in the science and art of health care and healing. This mission is carried out by physicians and researchers who are dedicated not only to unmatched clinical care, but also to ground breaking scientific activities. Our bioscientific and clinical staff are engaged in more than 1,700 active basic science, translational, and clinical studies spanning from the bench to the bedside. Studies range from whole-animal physiology to cell and molecular biology to bioengineering to clinical projects. Henry Ford scientists and physicians also participate in and lead many clinical trials that determine how to best treat disease. In fact much of our activities focus on studies that directly seek to understand mechanisms of disease and improve patient care. We are particularly proud of research teams from the Department of Public Health Sciences and the Center for Health Policy and Health Services Research who collaborate with members of the Henry Ford Medical Group as well as researchers in other states to enhance the quality of health care nationwide.

cardio research forum

Henry Ford Health System’s research program is one of the largest, most well-funded, and successful in Michigan. In 2011, Henry Ford ranked 224th of more than 2600 institutions receiving National Institutes of Health (NIH) funding from the United States government. The System receives more than $53.6 million in externally awarded grants, contracts, and sub-contracts, $24 million of which was awarded by the NIH.

Research programs in the Cardiovascular Division are among the most robust in the Health System. Opportunities are equally strong in each subspecialty of Cardiology. Fellows take full advantage of all of our research programs and routinely present at regional, national, and international society meetings. In 2016 our Division published more than 200 manuscripts, and Fellows are traditionally involved in most of the projects. Fellows also have the advantage of being paired with excellent research mentors who help guide them through their research activities from hypothesis generation, to IRB submission, to manuscript submission. Through didactic sessions, journal clubs, and one on one meetings Fellows are taught how to conduct thoughtful, ethical, and well performed cardiovascular research. To make the research experience even more appealing at Ford, Fellows have paid access to biostatisticians to help them with their research projects as well as institutional grants from the Graduate Medical Education Department to fund their projects.

Below you will find an example of recent activities within the Cardiovascular Division. We look forward to future Cardiology Fellows bringing with them new ideas and joining in the scholarly activities of our Division. The distinct advantage of training at Henry Ford is that you will be assured an outstanding clinical as well as academic training that will prepare you for a future life as a clinician and a scholar.

Recent and ongoing clinical trials

Structural heart disease/ interventional cardiology

  • LAMPOON- NIH sponsored trial led by Henry Ford Cardiologist Adam Greenbaum. The laceration of the interior mitral leaflet to prevent LVOT obstruction during transcatheter mitral valve implantation
  • MITRAL trial: Led by Henry Ford Cardiologist Bill O’Neill and Mayra Guerrero. The purpose of this trial is to establish the safety and feasibility of the Edwards SAPIEN XT™and SAPIEN 3™ device in patients with severe symptomatic calcific mitral valve disease with severe mitral annular calcification.
  • Amulet- The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN® left atrial appendage closure device in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the Amulet device or the WATCHMAN device.
  • TENDYNE Clinical Trial- The purpose of this study is to evaluate the safety and performance of the Tendyne Mitral Valve System. The study includes adult patients with symptomatic mitral regurgitation who are not suitable candidates for conventional mitral valve repair or replacement.
  • PARTNER III: To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients with severe, calcific aortic stenosis who are at low operative risk for standard aortic valve replacement (AVR).
  • EARLY TAVR: Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis.
  • GALILEO: Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes. To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE).
  • MANTA: Research study which tests the safety and effectiveness of a new vascular closure device to close the femoral access puncture that is created in patients who require this form of access in order to perform the planned procedure.
    VECTRACOR Device in PCI
  • Partner II- A prospective randomized, multicenter phase 3 trial evaluating the safety and effectiveness of Edwards SAPIEN XT transcatheter heart valve and delivery systems: NovaFlex (transfemoral) and Ascendra2 (transapical) in symptomatic, calcific, severe aortic stenosis with two population cohorts: 1) patients intermediate risk for surgical AVR (Cohort A - operable), and 2) patients not suitable for AVR (Cohort B - inoperable).
  • COAPT- A phase 3 trial evaluating safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe or severe functional mitral regurgitation (FMR) in high surgical risk subjects.
  • SURTAVI - Safety and efficacy study of the Medtronic CoreValve System in the treatment of severe, symptomatic aortic stenosis in intermediate risk subjects who need aortic valve replacement
  • SALUS- The Direct Flow Medical® Transcatheter Aortic Valve Replacement System US Pivotal Trial
  • Transatrial Pericardial Separation to Enhance the Safety of Subxiphoid Pericardial Access in Performing Lariat Left Atrial Appendage Ligation
  • CA-TAVR- Transcaval Access for Transcatheter Aortic Valve Replacement in Patients with No Good Option for Aortic Access
  • Mitral Implantation of Transcatheter Valves in Native Mitral Stenosis
  • Sentinel- Cerebral Protection in Transcatheter Aortic Valve Replacement
  • Preservation I- A placebo-controlled, multicenter, randomized, double blind phase 2 trial to evaluate the safety and effectiveness of IK-5001, intracoronary sodium alginate and calcium gluconate infusion, for the prevention of remodeling of LV and CHF after AMI and EF ≤ 35% or MI > 20%.
  • Turbulence- Clinical evaluation of the CADENCE Device in diagnosing coronary artery diseases
  • Regulate PCI- A randomized, open-label, multi-center, active-controlled, parallel group study to determine the efficacy and safety of the REG 1 anticoagulation system compared to Bivalrudin in patients undergoing percutaneous coronary intervention
  • CARIN- A Prospective, Comparative, Randomized, Multi-center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Peri-Procedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy
  • AEGIS I- A Phase 2 b, Multi-center, Randomized, Placebo Controlled, Dose – ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL 112 in Subjects with Acute Myocardial Infarction
  • Recover Right- The use of Impella RP support system in patients with right heart failure: a clinical safety and probable benefit study in patients with RV failure either: a) within 48 hours post-implantation of surgical LVAD (Cohort A); or b) postcardiotomy shock within 48 hours post surgery or post MI (Cohort B).
  • EVOLVE_AF_PCI- Evaluation of the Safety And Efficacy of Edoxaban vs Vitamin –K antagonist (VKA) in Subjects with Non- Valvular Atrial fibrillation (AF) following percutaneous Coronary Intervention (PCI) with Stent Placement.
  • EVOLVE II- A prospective, randomized, multicenter single-blind non-inferiority trial to assess the safety and effectiveness of the SYNERGY Everolimus-eluting platinum chromium stent (bioabsorbable polymer coating on abluminal surface) for the treatment of symptomatic CAD.
  • Apposition Trial- A prospective, randomized, double-blinded placebo controlled phase II trial of intra-coronary infusion of AMR-001, a bone marrow derived autologous CD34+ selected cell product, in patients with AMI and EF ≤ 45%.
  • PreSERVE- AMI- A prospective, randomized, double-blinded placebo controlled phase II trial of intra-coronary infusion of AMR-001, a bone marrow derived autologous CD34+ selected cell product, in patients with AMI and EF ≤ 45%.
  • SPIRI 201- Embrace- STEMI- A randomized, double-blind, placebo-controlled phase 2a trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia (MTP-131), IV administered mitochondrial targeting peptide, on reperfusion injury and infarct size in patients with first-time anterior STEMI treated with primary PCI.
  • ABSORB RCT- ABSORB III cohort will evaluate safety and effectiveness of Absorb BVS (Bioresorbable Vascular Scaffold) System compared to the XIENCE in treatment of ischemic heart disease caused by ≤2 de novo native coronary lesions in separate epicardial vessels.
  • Advance ASO Study: post-market surveillance of ASD closure using the Amplatzer device focusing on identifying risks for erosion events

Electrophysiology

  • BLOCk-CTI- Clinical Evaluation of the Blazer Open Irrigated Radiofrequency Ablation Catheter for the Treatment of Type 1 Atrial Flutter
  • CABANA- Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation a Multi-Center Prospective Open Label Clinical Trial
  • ENHANCE CRT- CRT implant strategy using the longest electrical delay for non-left bundle branch block patients/ A prospective, randomized postmarket pilot study
  • INGEVITY- Active Fixation and Passive Fixation Pace/Sense Lead Study
  • RAID- Ranolazine ICD Trial: To determine whether ranolazine administration will decrease the likelihood of a composite arrhythmia endpoint consisting of ventricular tachycardia or ventricular fibrillation (VT/VF) requiring antitachycardia pacing (ATP), ICD shocks, or death
  • S-ICD PAS- S-ICD® System Post Approval Study

Noninvasive imaging

  • REG-SPECT- Characteristics and outcomes of patients selected to undergo pharmacologic myocardial perfusion testing using regadenoson-facilitated single-photon emission computerized tomography (SPECT)
  • GE-122-020 (ADMIRE-ICD): AdreView™ Myocardial Imaging for Risk Evaluation – A multicenter trial to guide ICD implantation in NYHA class II & III heart failure patients with 30%≤LVEF≤35%.
  • ISCHEMIA trial- (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) – study to determine whether an invasive (INV) strategy of routine early cardiac catheterization with intent for optimal revascularization in addition to optimal medical therapy in patients with stable ischemic heart disease (SIHD) and at least moderate ischemia on stress imaging reduces the incidence of the composite of cardiovascular death or nonfatal myocardial infarction compared with a conservative (CON) strategy of optimal medical therapy alone with cardiac catheterization and revascularization reserved for patients with refractory angina, acute coronary syndrome, acute ischemic heart failure or resuscitated cardiac arrest. Sub-studies include:
    • ISCHEMIA-CKD (for patients who have eGFR <30 or on dialysis). Purpose is to determine whether the INV strategy reduces the incidence of death or nonfatal myocardial infarction compared with CON in participants with advanced CKD
    • ISCHEMIA-CIAO (for patients who lack CTA evidence of obstructive CAD and cannot be randomized to ISCHEMIA main trial) Purpose is to investigate the association between changes in ischemia over one year and changes in angina over one year in participants excluded from the main ISCHEMIA study based on the absence of obstructive CAD.
  • Discovery trial - A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis.
  • TAILOR-PCI- Prospective, randomized trial testing the hypothesis that after PCI, ticagrelor 90 mg bid is superior to clopidogrel 75 mg qd in reducing a composite endpoint of MACE in CYP2C19 reduced function allele patients

Heart failure

  • Pharmacogenetics of the B-type Natriuretic Peptide Pathway
  • Impact of Race and Genetic Factors on Beta-Blocker Effectiveness in Heart Failure
  • Endeavor trial - A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
  • Innovate-HF- Vagal stimulation device in heart failure
  • TRUE-AHF- Trial of Ultratide’s efficacy and safety in patients with acute heart failure
  • COSMIC-HF- Chronic oral study of myosin activation to increase contractility in heart failure
  • RELAX-AHF- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure: a randomized, placebo-controlled trial
  • SOCRATES- soluble guanylate cyclase stimulator in heart failure
  • IMED- noninvasive lung water quantification
  • Cardioxyl- inodilator and lusitrope without increased oxygen demand
  • BMS-STANDUP: The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986231in subjects with heart failure (HF) and reduced systolic function (LVEF < 40%) who are admitted to the hospital with signs and symptoms of acute decompensated heart failure (ADHF). CLR325X2202: To determine the safety and tolerability of an 18-hour IV infusion of CLR325 in chronic stable heart failure patients. (PI-Lanfear)(IRB#10285)
  • PANACHE: A multicenter, randomized, parallel group, double blind, dose-finding phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure and preserved ejection fraction.
  • GALACTIC : A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
  • OBSERVE: Prospective, randomized (1:1), placebo-controlled, double blind, study of ivabradine (Corlanor®) begun at the time of discharge from the observation unit for a cohort of predominantly (but not exclusively) African American patients with acute heart failure (HF). The primary endpoint will be change in heart rate from discharge to 28 (+/-2) days.
  • PANTHEON: Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamics effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction
  • DEFINE:A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and NTproBNP), symptoms, health status, and quality of life in patients with type 2 diabetes and chronic heart failure with reduced systolic function. Substudies will also be conducted for exploratory biomarker analyses and effects on arrhythmia burden.
  • GRAHF: Genomic Analysis of Enhanced Response to Heart Failure Therapy in African Americans. The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine (FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction (HFrEF) when compared to similar white cohorts.
  • PARAGON: A multicenter, randomized, double-blind, parallel group,active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction.
  • REVIVAL: Registry Evaluation of Vital Information for VADS in Ambulatory Life.
  • SOPRANO: A prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of macitentan in patients with pulmonary hypertension after left ventricular assist device implantation.
  • TROUPER: The primary objectives of this study are to compare the effects of oral tolvaptan plus augmented loop diuretic versus augmented loop diuretic on short term changes in body weight and signs and symptoms of congestion in patients presenting with worsening congestive heart failure in the outpatient setting with and without prespecified post hoc stratification based on baseline copeptin level.
  • PREVENT: Prevention of nonsurgical bleeding by management of Heart Mate II with Antiplatelet therapy.
  • LVAD II- Safety and Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
  • TR- Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Clinical and preventive cardiology

  • Henry Ford Heart Score Trial - Randomized Trial of Low-risk Chest Pain in the Emergency Department
  • Symptoms of ACS: substudy of the TRAPID-AMI study
  • REACTION-US Trial- Diagnostic Utility of a delta 1-hr rule-out AMI protocol using hs-cTnT
  • STOP-CP Trial- hs-CTnT to Optimize Chest Pain Risk Stratification
  • Siemens hs-cTnI Trial- Specimen Collection in the Emergency Department for the Assessment of Clinical Performance of Troponin Assays
  • HF-PROACTIVE (Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy)- Randomized, controlled trial with a target enrollment of 30 patients at risk for future heart failure using novel markers of early cardiac damage to determine if exercise training can improve these emerging markers as well as overall fitness and quality of life.
  • TACT2 (Trial to Assess Chelation Therapy)- Randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction
  • STRYD (STTR Phase I:Using Mechanical Power for Cardiac Risk Stratification and Rehabilitation)- Pilot investigation of the relationship between mechanical power and cardiorespiratory fitness in patients with heart failure
  • THEMIS trial - effect of Ticagrelor on Health outcomes in diabEtes Mellitus patients Intervention Study. This is a Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus.
  • HEART Camp -(Heart Failure Exercise and Resistance Training): Evaluate the effect of HEART Camp strategies (weekly coaching meetings and education discussions/lectures) on adherence to exercise.
  • AUGUSTUS- An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention
  • CANTOS-Does Canakinumab treatment of patients with MI and elevated hsCRP prevent CV events? Phase III multicenter randomized, parallel group, placebo controlled double blind event driven global clinical trial.
  • ENDEAVOUR - A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
  • CHALLENGE - NCIC CTG CO.21: A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial
  • Nimbleheart – Pilot assessment of a novel telemetry monitoring system in cardiac rehabilitation.
  • HFpEF - Novel cardiac rehabilitation in Heart Failure with Preserved Ejection Fraction. Comparison of standard training methods vs higher intensity aerobic interval and resistance training on fitness and quality of life in patients with HFpEF.
  • CTO-PCI – Evaluation of Exercise Capacity, as Measured by Peak Oxygen Uptake, Before and After Percutaneous Revascularization of Chronic Total Occlusion.

Recent or ongoing clinical research topics/opportunities

  • Cardiac rehabilitation and chronic heart failure
  • Exercise training for heart failure and PVD
  • Exercise training in patients with ICDs
  • Exercise training in patient with heart failure and preserved ejection fraction
  • Association of clinical and demographic factors with cardiopulmonary performance in heart failure
  • Cardiorespiratory fitness in patients with left ventricular assist devices
  • Timing of referral to cardiac rehabilitation after cardiac events
  • Beta blockers in patients with heart failure with normal and reduced ejection fraction
  • Renal dysfunction in patients with heart failure
  • Valve repair during left ventricular assist device implantation
  • ICD settings and outcomes
  • Role of nonpharmacologic EP-based interventions in improving outcomes in patients hospitalized for heart failure
  • Arrhythmia and shock burden in different ICD populations
  • Surface ECG findings and predicting myocardial viability
  • Fragmented QRS studies
  • Cardiac biomarkers and outcomes in acute coronary syndrome
  • Cardiac biomarkers in the clinical decision unit setting
  • Cardiac biomarkers in hypertensive crisis
  • Cardiac biomarkers in patients undergoing cardiotoxic chemotherapy
  • Chest pain qualities in acute coronary syndrome
  • HEART score in the clinical setting
  • Beta blockers and outcomes in STEMI
  • Computer ECG read clinical correlations
  • LBBB and the diagnosis of myocardial infarction
  • 3D echocardiography and evaluation of cardiac function
  • Traditional versus accelerated protocols in echo stress testing
  • Assessing parameters to quantify the size and significance of pericardial effusions
  • Different imaging modalities in assessing left atrial appendage size/ morphology
  • Characteristics and outcomes of different nuclear pharmacologic stress drugs
  • Nuclear imaging and cardiac dyssynchrony
  • Traditional versus accelerated protocols in nuclear stress testing
  • Racial differences and outcomes in SPECT
  • Regadenoson PET outcomes
  • MIBG studies
  • Relationship of clinical/ imaging findings with coronary disease on coronary CT angiography
  • Demographic variables and coronary plaque composition and burden in CTA
  • Predictive value of coronary CT angiography on clinical outcomes
  • Cerebral protection during transcatheter aortic valve replacement
  • Epicardial fat in various transcatheter interventions
  • Optimal views in transcatheter therapies
  • Outcomes in PFO closure
  • Quantitative coronary angiography versus clinical interpretation
  • Radial versus femoral access in STEMI
  • Insulin resistance and atherosclerosis
  • Psoriasis and CAD
  • Yoga and cardiovascular outcomes
  • Omega-3 polyunsaturated fatty acids and ventricular arrhythmias

Basic science research opportunities

  • Cardiac Metabolism in Heart Failure
  • The Mitochondria in Heart Failure
  • Adenosine Receptor Agonists and Apyrases for the Treatment of Heart Failure
  • Mitochondria Targeting Peptides for the Treatment of Heart Failure
  • The Apelin Signaling System in Heart Failure
  • Stem Cell Conditioned Media for the Treatment of Heart Failure
  • Cytokines, Chemokines and Growth Factors in the Failing Heart
  • ARBs and Neprilysin inhibitors for the Treatment of Heart Failure and Cardiorenal Syndrome
  • Genetic variation and gene expression in the natriuretic peptide pathway
  • Abnormalities of Contractility and Relaxation in Heart Failure
  • Myocardial Augmentation for the Treatment of Heart Failure
  • Role of Interstitial Fibrosis in Heart Failure (HFpEF and HFrEF)
  • Abnormalities of Autonomic Regulation in Heart Failure

Clinical registries

  • The FIT Project- The Henry Ford Exercise Testing Project- stress testing database
  • FIT-CPX- The Henry Ford Hospital Cardiopulmonary Exercise Testing Project
  • Henry Ford STEMI Registry
  • Henry Ford Genomic Registry
  • Henry Ford Liver and Renal Transplant Registry
  • Henry Ford Cardiomyopathy Registry
  • Henry Ford SPECT Registry
  • Henry Ford Coronary CTA database
  • Advanced cardiac imaging consortium Michigan CTA database
  • Henry Ford Cardiac MRI database
  • HF-Action- Exercise training in Heart Failure
  • Multicenter cardiac sarcoidosis registry
  • Retrospective HF and MI databases utilizing Corporate Data Store
  • National Cardiovascular Data Registry
  • Blue Cross Blue Shield of Michigan BMC2-PCI Registry - Percutaneous coronary intervention registry
  • STS/ACC TVT Registry - Transcatheter valve replacement and repair procedures
  • ACC LAAO Registry- covers Left Atrial Appendage Closure
  • TOPAS-TAVI- Transcatheter Aortic Valve Implantation in Patients with Low-Flow, Low Gradient Aortic Stenosis (Truly or Pseudo Severe Aortic Valve Stenosis). A Prospective Multicenter Registry.
  • PROGRESS CTO REGISTRY- Multi center Registry of Chronic total Occlusion Interventions
  • EAGLE Registry- Close Chested Epicardial Ligation of the Left Atrial Appendage in Atrial Fibrillation Patients Registry: A Multicenter Prospective Observational Cohort
  • SCORE- Electrophysiology St. Jude Medical Product Longevity and Performance Registry
  • IRAD registry - aortic dissection registry
  • Michigan Anticoagulation Quality Improvement Initiative
  • TRIUMPH registry- Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patient’s Health Status Registry
  • THEME Registry- enrolling patients who receive TandemLife devices
  • USPella Registry- enrolling patients who receive Impella devices
  • MITRAL Registry- mitral valve in valve, valve in ring, valve in MAC registry for transcatheter mitral valve implantation using Sapien valves in the mitral position
Information for Applicants
Interested in applying to one of our programs?